NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT05413850 2026-03-02
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT07145177 2025-12-18
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Not yet recruiting
NCT06516510 2025-09-25
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Blue Earth Therapeutics Ltd
Phase EARLY_PHASE1 Terminated
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting